Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Technetium Tc 99m trofolastat - Progenics Pharmaceuticals

Next Previous
X
Search
Drug Profile

Technetium Tc 99m trofolastat - Progenics Pharmaceuticals

Alternative Names: 1404; 99mTc-MIP1404; 99mTc-trofolastat; F-1311; LNTH-1404; MIP-1404; MP-1404; PSMA-targeted imaging agent 1404

Latest Information Update: 13 Apr 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer FUJIFILM Toyama Chemical; Molecular Insight Pharmaceuticals; Progenics Pharmaceuticals; Turku University Hospital
  • Class Antineoplastics; Imaging agents; Imidazoles; Organotechnetium compounds; Radiopharmaceuticals; Small molecules; Technetium compounds
  • Mechanism of Action Diagnostic imaging enhancers; Glutamate carboxypeptidase II inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 21 Mar 2022 Phase-III clinical trials in Prostate cancer (Diagnosis, Metastatic disease, In adults, In the elderly) in Finland (IV) (EudraCT2021-000486-33)
  • 06 Jul 2020 Phase-III clinical trials in Prostate cancer (Diagnosis, Metastatic disease) (IV), prior to July 2020 (Progenics Pharmaceuticals pipeline, July 2020)
  • 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top